Physician profile
John M Kunkel
NPI 1366803843
$19,107.52
in general payments reported to CMS, 2019-2025
9 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,209 · 2021: $2,428 · 2022: $12K · 2023: $689 · 2024: $1,445 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,507 · Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,506.75 |
| Food and Beverage | $862.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $6,400.37 | 2022-2024 | |
| Medinc of Texas | $4,896.16 | 2022 | |
| Liberty Surgical INC. | $2,400.00 | 2021 | |
| Novus Surgical Solutions LLC | $2,284.73 | 2022 | |
| Supreme Orthopedic Systems, LLC | $2,196.00 | 2019 | |
| Novus Surgical Consultants | $822.34 | 2022-2025 | |
| Smith+Nephew, INC. | $60.01 | 2021-2022 | |
| Depuy Synthes Sales INC. | $34.50 | 2022 | |
| Merck Sharp & Dohme LLC | $13.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kunkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.